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Ovarian cancer is the number one cause of death due to
gynecological malignancies, and the fifth leading cause
of death in cancer in women. While surgical debulking
and chemotherapy cause an initial remission in disease,
approximately 75% of patients will relapse. The relapse
is characterized by chemotherapy refractory disease.
Currently there are no definitive second line treatments
for patients who fail standard of care. Patients with
ovarian cancer have a 5-year survival rate of 25-30%,
making it one of the most aggressive malignancies.
We have designed a new cell therapy by using the
patient’s innate immune system (monocytes primed with
Interferon Alpha and Gamma) to kill metastatic lesions
of the peritoneal cavity.
Monocytes isolated from patients with therapy resistant
ovarian cancer and stimulated with interferons alpha and
gamma are potent killers of tumor cell lines in vitro. We
have also found that patient monocytes are more cytotoxic
than age match healthy controls. We have shown that the
major mechanism of monocyte-mediated killing is the up
regulation of TRAIL on monocytes. Ovarian cancer cell
death is mediated in a Caspase-8 dependent manner.
Furthermore, we have shown that the non-classical
(CD14loCD16+) subset of monocytes is more cytotoxic
than the classical (CD14+CD16-) subset. Finally, we have
shown that this therapy is effective in a mouse model of
ovarian cancer. Based upon these results we are preparing
an investigational new drug (IND) with the FDA to test
this therapy in human subjects.
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